LIF and breast cancer: Interestingly, the restoration of LIFR in highly aggressive MDA-MB-231 cells by treatment with a histone deacetylase inhibitor restores STAT3 signaling downstream of LIF:LIFR, which has been proposed to promote drug resistance by breast cancer cells [106].